Michael Harrop
Active member
Article https://www.nytimes.com/2023/10/16/health/long-covid-serotonin.html
Study https://www.cell.com/cell/fulltext/S0092-8674(23)01034-6
Study https://www.cell.com/cell/fulltext/S0092-8674(23)01034-6
Highlights
- Long COVID is associated with reduced circulating serotonin levels
- Serotonin depletion is driven by viral RNA-induced type I interferons (IFNs)
- IFNs reduce serotonin through diminished tryptophan uptake and hypercoagulability
- Peripheral serotonin deficiency impairs cognition via reduced vagal signaling
Summary
Post-acute sequelae of COVID-19 (PASC, “Long COVID”) pose a significant global health challenge. The pathophysiology is unknown, and no effective treatments have been found to date. Several hypotheses have been formulated to explain the etiology of PASC, including viral persistence, chronic inflammation, hypercoagulability, and autonomic dysfunction. Here, we propose a mechanism that links all four hypotheses in a single pathway and provides actionable insights for therapeutic interventions. We find that PASC are associated with serotonin reduction. Viral infection and type I interferon-driven inflammation reduce serotonin through three mechanisms: diminished intestinal absorption of the serotonin precursor tryptophan; platelet hyperactivation and thrombocytopenia, which impacts serotonin storage; and enhanced MAO-mediated serotonin turnover. Peripheral serotonin reduction, in turn, impedes the activity of the vagus nerve and thereby impairs hippocampal responses and memory. These findings provide a possible explanation for neurocognitive symptoms associated with viral persistence in Long COVID, which may extend to other post-viral syndromes.
- Format correct?
- Yes